OpenURL Connection Search

Select item for more details and to access through your institution.

Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor.
Published in:
ChemMedChem, 2018, v. 13, n. 5, p. 437, doi. 10.1002/cmdc.201700718
By:
- Collin, Marie‐Pierre;
- Lobell, Mario;
- Hübsch, Walter;
- Brohm, Dirk;
- Schirok, Hartmut;
- Jautelat, Rolf;
- Lustig, Klemens;
- Bömer, Ulf;
- Vöhringer, Verena;
- Héroult, Mélanie;
- Grünewald, Sylvia;
- Hess‐Stumpp, Holger
Publication type:
Article
Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.
Published in:
British Journal of Clinical Pharmacology, 2012, v. 73, n. 2, p. 219, doi. 10.1111/j.1365-2125.2011.04064.x
By:
- Weber, Olaf;
- Willmann, Stefan;
- Bischoff, Hilmar;
- Li, Volkhart;
- Vakalopoulos, Alexandros;
- Lustig, Klemens;
- Hafner, Frank-Thorsten;
- Heinig, Roland;
- Schmeck, Carsten;
- Buehner, Klaus
Publication type:
Article
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Published in:
Cardiovascular Research, 2009, v. 82, n. 1, p. 30, doi. 10.1093/cvr/cvp002
By:
- Stefan Schäfer;
- Peter Ellinghaus;
- Wiebke Janssen;
- Frank Kramer;
- Klemens Lustig;
- Hendrik Milting;
- Raimund Kast;
- Martina Klein
Publication type:
Article
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models.
Published in:
International Journal of Cancer, 2019, v. 145, n. 5, p. 1346, doi. 10.1002/ijc.32224
By:
- Grünewald, Sylvia;
- Politz, Oliver;
- Bender, Sebastian;
- Héroult, Mélanie;
- Lustig, Klemens;
- Thuss, Uwe;
- Kneip, Christoph;
- Kopitz, Charlotte;
- Zopf, Dieter;
- Collin, Marie‐Pierre;
- Boemer, Ulf;
- Ince, Stuart;
- Ellinghaus, Peter;
- Mumberg, Dominik;
- Hess‐Stumpp, Holger;
- Ziegelbauer, Karl
Publication type:
Article
Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model.
Published in:
ChemMedChem, 2016, v. 11, n. 2, p. 199, doi. 10.1002/cmdc.201500269
By:
- von Nussbaum, Franz;
- Li, Volkhart M.;
- Meibom, Daniel;
- Anlauf, Sonja;
- Bechem, Martin;
- Delbeck, Martina;
- Gerisch, Michael;
- Harrenga, Axel;
- Karthaus, Dagmar;
- Lang, Dieter;
- Lustig, Klemens;
- Mittendorf, Joachim;
- Schäfer, Martina;
- Schäfer, Stefan;
- Schamberger, Jens
Publication type:
Article
Cover Picture: Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases (ChemMedChem 7/2015).
Published in:
ChemMedChem, 2015, v. 10, n. 7, p. 1117, doi. 10.1002/cmdc.201590019
By:
- von Nussbaum, Franz;
- Li, Volkhart M.‐J.;
- Allerheiligen, Swen;
- Anlauf, Sonja;
- Bärfacker, Lars;
- Bechem, Martin;
- Delbeck, Martina;
- Fitzgerald, Mary F.;
- Gerisch, Michael;
- Gielen‐Haertwig, Heike;
- Haning, Helmut;
- Karthaus, Dagmar;
- Lang, Dieter;
- Lustig, Klemens;
- Meibom, Daniel;
- Mittendorf, Joachim;
- Rosentreter, Ulrich;
- Schäfer, Martina;
- Schäfer, Stefan;
- Schamberger, Jens
Publication type:
Article
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
Published in:
ChemMedChem, 2015, v. 10, n. 7, p. 1163, doi. 10.1002/cmdc.201500131
By:
- von Nussbaum, Franz;
- Li, Volkhart M.‐J.;
- Allerheiligen, Swen;
- Anlauf, Sonja;
- Bärfacker, Lars;
- Bechem, Martin;
- Delbeck, Martina;
- Fitzgerald, Mary F.;
- Gerisch, Michael;
- Gielen‐Haertwig, Heike;
- Haning, Helmut;
- Karthaus, Dagmar;
- Lang, Dieter;
- Lustig, Klemens;
- Meibom, Daniel;
- Mittendorf, Joachim;
- Rosentreter, Ulrich;
- Schäfer, Martina;
- Schäfer, Stefan;
- Schamberger, Jens
Publication type:
Article

Found: 7

Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor.

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models.

Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model.

Cover Picture: Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases (ChemMedChem 7/2015).

Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.